BIMEKIZUMAB EFFICACY BY BODY REGION IN PLAQUE PSORIASIS: COMPARATIVE ANALYSES FROM FOUR PHASE 3/3B STUDIES

被引：0

作者：

Savage, Laura ^{[1
]}

Pinter, Andreas ^{[2
]}

Crowley, Jeffrey ^{[3
]}

Kerkhof, Peter van de ^{[4
]}

Armstrong, April ^{[5
]}

Kavanagh, Sarah ^{[6
]}

Wiegratz, Susanne ^{[7
]}

Hoepken, Bengt ^{[7
]}

Warren, Richard B. ^{[8
,9
]}

机构：

[1] Leeds Teaching Hosp NHS Trust, Leeds, England

[2] Univ Hosp Frankfurt, Frankfurt, Germany

[3] Bakersfield Dermatol, Bakersfield, CA USA

[4] Radboud Univ Nijmegen, Nijmegen, Netherlands

[5] Univ Calif Los Angeles UCLA, Los Angeles, CA USA

[6] UCB Pharm, Morrisville, NY USA

[7] UCB Pharm, Monheim, Germany

[8] Northern Care Alliance NHS Fdn Trust, Dermatol Ctr, Manchester, England

[9] Manchester Univ NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Manchester Acad Hlth Sci Ctr, Manchester Acad Hlth Sci Ctr Manchester, Manchester, England

来源：

ACTA DERMATO-VENEREOLOGICA | 2024年 / 104卷

关键词：

DOUBLE-BLIND; MULTICENTER; MODERATE; SAFETY;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P-061

引用

页数：102

共 50 条

[21] Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial
Blauvelt, Andrew
Wu, Jashin J.
Reich, Kristian
Gooderham, Melinda
Lebwohl, Mark
White, Katy
Cross, Nancy
Cioffi, Christopher
Papp, Kim A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB139 - AB139
[22] Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
Asahina, Akihiko
Okubo, Yukari
Morita, Akimichi
Tada, Yayoi
Igarashi, Atsuyuki
Langley, Richard G.
Deherder, Delphine
Matano, Mizuho
Vanvoorden, Veerle
Wang, Maggie
Ohtsuki, Mamitaro
Nakagawa, Hidemi
DERMATOLOGY AND THERAPY, 2023, 13 (03) : 751 - 768
[23] Bimekizumab versus secukinumab in plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) responses accompanying achievement of complete skin clearance in the phase 3b BE RADIANT trial
Gottlieb, Alice B.
Langley, Richard G.
Warren, Richard B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB25 - AB25
[24] Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
Akihiko Asahina
Yukari Okubo
Akimichi Morita
Yayoi Tada
Atsuyuki Igarashi
Richard G. Langley
Delphine Deherder
Mizuho Matano
Veerle Vanvoorden
Maggie Wang
Mamitaro Ohtsuki
Hidemi Nakagawa
Dermatology and Therapy, 2023, 13 : 751 - 768
[25] Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials
Strober, Bruce
Warren, Richard B.
Foley, Peter
Gooderham, Melinda
Thaci, Diamant
Cullen, Eva
Cioffi, Christopher
Peterson, Luke
Madden, Cynthia
Armstrong, April
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB76 - AB76
[26] Bimekizumab response maintenance in high-impact areas in patients with moderate to severe plaque psoriasis: Pooled results through 96 weeks of the BE SURE, BE READY, and BE RADIANT phase 3/3b trials
Merola, Joseph F.
Warren, Richard B.
Han, George
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB24 - AB24
[27] Bimekizumab versus secukinumab in plaque psoriasis: Reduction in body surface area affected by psoriasis translates into benefits in patient-perceived itching, skin pain, and scaling and health-related quality of life in the BE RADIANT phase 3b trial
Augustin, Matthias
Gooderham, Melinda
Gottlieb, Alice B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB25 - AB25
[28] BIMEKIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
Thaci, Diamant
Gottlieb, Alice B.
Asahina, Akihiko
Lebwohl, Mark
McInnes, Iain B.
Warren, Richard
Boehncke, Wolf-Henning
Ink, Barbara
Bajracharya, Rajan
Coarse, Jason
Merola, Joseph F.
ACTA DERMATO-VENEREOLOGICA, 2024, 104
[29] Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48-144) of the BE RADIANT phase 3b trial
Strober, Bruce
Puig, Luis
Blauvelt, Andrew
Thaci, Diamant
Elewski, Boni
Wang, Maggie
Vanvoorden, Veerle
Deherder, Delphine
Staelens, Fabienne
Wiegratz, Susanne
Paul, Carle
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB21 - AB21
[30] Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48-144) of the BE RADIANT Phase 3b Trial
Strober, Bruce
Puig, Luis
Blauvelt, Andrew
Thaci, Diamant
Elewski, Boni
Wang, Maggie
Vanvoorden, Veerle
Deherder, Delphine
Staelens, Fabienne
Wiegratz, Susanne
Merola, Joseph F.
Paul, Carle
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2841 - 2844

← 1 2 3 4 5 →